Logo image of ICLR

ICON PLC (ICLR) Stock Fundamental Analysis

USA - NASDAQ:ICLR - IE0005711209 - Common Stock

192.31 USD
+17.31 (+9.89%)
Last: 10/1/2025, 8:58:40 PM
192.31 USD
0 (0%)
After Hours: 10/1/2025, 8:58:40 PM
Fundamental Rating

5

Overall ICLR gets a fundamental rating of 5 out of 10. We evaluated ICLR against 56 industry peers in the Life Sciences Tools & Services industry. ICLR has an average financial health and profitability rating. ICLR is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

ICLR had positive earnings in the past year.
In the past year ICLR had a positive cash flow from operations.
In the past 5 years ICLR has always been profitable.
In the past 5 years ICLR always reported a positive cash flow from operatings.
ICLR Yearly Net Income VS EBIT VS OCF VS FCFICLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

ICLR's Return On Assets of 4.78% is fine compared to the rest of the industry. ICLR outperforms 76.79% of its industry peers.
ICLR's Return On Equity of 8.31% is fine compared to the rest of the industry. ICLR outperforms 76.79% of its industry peers.
ICLR has a better Return On Invested Capital (6.57%) than 75.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ICLR is significantly below the industry average of 14.87%.
The 3 year average ROIC (5.80%) for ICLR is below the current ROIC(6.57%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.78%
ROE 8.31%
ROIC 6.57%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ICLR Yearly ROA, ROE, ROICICLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

The Profit Margin of ICLR (9.82%) is better than 73.21% of its industry peers.
In the last couple of years the Profit Margin of ICLR has declined.
ICLR has a Operating Margin of 14.43%. This is in the better half of the industry: ICLR outperforms 78.57% of its industry peers.
In the last couple of years the Operating Margin of ICLR has remained more or less at the same level.
ICLR has a Gross Margin of 28.65%. This is in the lower half of the industry: ICLR underperforms 76.79% of its industry peers.
In the last couple of years the Gross Margin of ICLR has remained more or less at the same level.
Industry RankSector Rank
OM 14.43%
PM (TTM) 9.82%
GM 28.65%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
ICLR Yearly Profit, Operating, Gross MarginsICLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

5

2. Health

2.1 Basic Checks

ICLR has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ICLR has been reduced compared to 1 year ago.
ICLR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ICLR has been reduced compared to a year ago.
ICLR Yearly Shares OutstandingICLR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ICLR Yearly Total Debt VS Total AssetsICLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

An Altman-Z score of 2.26 indicates that ICLR is not a great score, but indicates only limited risk for bankruptcy at the moment.
ICLR has a Altman-Z score (2.26) which is comparable to the rest of the industry.
The Debt to FCF ratio of ICLR is 3.45, which is a good value as it means it would take ICLR, 3.45 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 3.45, ICLR is doing good in the industry, outperforming 76.79% of the companies in the same industry.
ICLR has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
ICLR has a Debt to Equity ratio (0.35) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 3.45
Altman-Z 2.26
ROIC/WACC0.8
WACC8.24%
ICLR Yearly LT Debt VS Equity VS FCFICLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

A Current Ratio of 1.29 indicates that ICLR should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.29, ICLR is doing worse than 82.14% of the companies in the same industry.
ICLR has a Quick Ratio of 1.29. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.29, ICLR is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 1.29
ICLR Yearly Current Assets VS Current LiabilitesICLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

ICLR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.36%.
Measured over the past years, ICLR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.23% on average per year.
The Revenue has decreased by -2.91% in the past year.
Measured over the past years, ICLR shows a very strong growth in Revenue. The Revenue has been growing by 24.17% on average per year.
EPS 1Y (TTM)-5.36%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-13.07%
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.85%

3.2 Future

ICLR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.25% yearly.
Based on estimates for the next years, ICLR will show a small growth in Revenue. The Revenue will grow by 2.36% on average per year.
EPS Next Y-3.63%
EPS Next 2Y1.23%
EPS Next 3Y3.88%
EPS Next 5Y7.25%
Revenue Next Year-3.49%
Revenue Next 2Y-1.07%
Revenue Next 3Y1.05%
Revenue Next 5Y2.36%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ICLR Yearly Revenue VS EstimatesICLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ICLR Yearly EPS VS EstimatesICLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20 25

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

ICLR is valuated correctly with a Price/Earnings ratio of 14.54.
ICLR's Price/Earnings ratio is rather cheap when compared to the industry. ICLR is cheaper than 96.43% of the companies in the same industry.
ICLR's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.79.
A Price/Forward Earnings ratio of 13.40 indicates a correct valuation of ICLR.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ICLR indicates a rather cheap valuation: ICLR is cheaper than 94.64% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.21. ICLR is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 14.54
Fwd PE 13.4
ICLR Price Earnings VS Forward Price EarningsICLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ICLR is valued cheaper than 100.00% of the companies in the same industry.
ICLR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ICLR is cheaper than 92.86% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.11
EV/EBITDA 11.59
ICLR Per share dataICLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

The decent profitability rating of ICLR may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.95
EPS Next 2Y1.23%
EPS Next 3Y3.88%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ICLR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICON PLC

NASDAQ:ICLR (10/1/2025, 8:58:40 PM)

After market: 192.31 0 (0%)

192.31

+17.31 (+9.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)07-23 2025-07-23/amc
Earnings (Next)10-22 2025-10-22/amc
Inst Owners102.62%
Inst Owner Change-2.94%
Ins Owners0.65%
Ins Owner ChangeN/A
Market Cap14.96B
Analysts79.2
Price Target220.12 (14.46%)
Short Float %3.69%
Short Ratio2.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.05%
Min EPS beat(2)-0.34%
Max EPS beat(2)0.23%
EPS beat(4)1
Avg EPS beat(4)-3.93%
Min EPS beat(4)-14.41%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.35%
EPS beat(12)3
Avg EPS beat(12)-1.69%
EPS beat(16)6
Avg EPS beat(16)-1.11%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-2.61%
Max Revenue beat(2)-0.23%
Revenue beat(4)0
Avg Revenue beat(4)-2.78%
Min Revenue beat(4)-6.75%
Max Revenue beat(4)-0.23%
Revenue beat(8)0
Avg Revenue beat(8)-2.61%
Revenue beat(12)0
Avg Revenue beat(12)-2.36%
Revenue beat(16)0
Avg Revenue beat(16)-2.13%
PT rev (1m)-1.28%
PT rev (3m)20.56%
EPS NQ rev (1m)-0.62%
EPS NQ rev (3m)-2.05%
EPS NY rev (1m)-0.56%
EPS NY rev (3m)-0.51%
Revenue NQ rev (1m)-0.34%
Revenue NQ rev (3m)0.8%
Revenue NY rev (1m)-0.49%
Revenue NY rev (3m)0.27%
Valuation
Industry RankSector Rank
PE 14.54
Fwd PE 13.4
P/S 1.85
P/FCF 15.11
P/OCF 12.94
P/B 1.57
P/tB N/A
EV/EBITDA 11.59
EPS(TTM)13.23
EY6.88%
EPS(NY)14.35
Fwd EY7.46%
FCF(TTM)12.73
FCFY6.62%
OCF(TTM)14.86
OCFY7.73%
SpS104.02
BVpS122.86
TBVpS-38.32
PEG (NY)N/A
PEG (5Y)0.95
Profitability
Industry RankSector Rank
ROA 4.78%
ROE 8.31%
ROCE 8.31%
ROIC 6.57%
ROICexc 6.76%
ROICexgc 82.41%
OM 14.43%
PM (TTM) 9.82%
GM 28.65%
FCFM 12.23%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexcg growth 3Y-4.45%
ROICexcg growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score5
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 3.45
Debt/EBITDA 2.18
Cap/Depr 43.25%
Cap/Sales 2.05%
Interest Coverage 250
Cash Conversion 74.49%
Profit Quality 124.6%
Current Ratio 1.29
Quick Ratio 1.29
Altman-Z 2.26
F-Score5
WACC8.24%
ROIC/WACC0.8
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.36%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-13.07%
EPS Next Y-3.63%
EPS Next 2Y1.23%
EPS Next 3Y3.88%
EPS Next 5Y7.25%
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.85%
Revenue Next Year-3.49%
Revenue Next 2Y-1.07%
Revenue Next 3Y1.05%
Revenue Next 5Y2.36%
EBIT growth 1Y3.81%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year0.82%
EBIT Next 3Y3.29%
EBIT Next 5Y4.07%
FCF growth 1Y160.15%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y116.49%
OCF growth 3Y15.78%
OCF growth 5Y25.55%